Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study
-
Published:2018
Issue:4
Volume:107
Page:375-386
-
ISSN:0028-3835
-
Container-title:Neuroendocrinology
-
language:en
-
Short-container-title:Neuroendocrinology
Author:
Rindi GuidoORCID, Klersy Catherine, Albarello Luca, Baudin Eric, Bianchi Antonio, Buchler Markus W., Caplin Martyn, Couvelard Anne, Cros JérômeORCID, de Herder Wouter W.ORCID, Delle Fave Gianfranco, Doglioni Claudio, Federspiel Birgitte, Fischer Lars, Fusai Giuseppe, Gavazzi Francesca, Hansen Carsten P., Inzani Frediano, Jann Henning, Komminoth Paul, Knigge Ulrich P., Landoni Luca, La Rosa Stefano , Lawlor Rita T., Luong Tu V., Marinoni Ilaria, Panzuto F., Pape Ulrich-Frank, Partelli Stefano, Perren AurelORCID, Rinzivillo Maria, Rubini Corrado, Ruszniewski Philippe, Scarpa Aldo, Schmitt Anja, Schinzari Giovanni, Scoazec Jean-Yves, Sessa Fausto, Solcia Enrico, Spaggiari Paola, Toumpanakis Christos, Vanoli Alessandro, Wiedenmann Bertram, Zamboni Giuseppe, Zandee Wouter T.ORCID, Zerbi Alessandro, Falconi MassimoORCID
Abstract
Background: The World Health Organization (WHO) and the American Joint Cancer Committee (AJCC) modified the grading of pancreatic neuroendocrine neoplasms from a three-tier (WHO-AJCC 2010) to a four-tier system by introducing the novel category of NET G3 (WHO-AJCC 2017). Objectives: This study aims at validating the WHO-AJCC 2017 and identifying the most effective grading system. Method: A total of 2,102 patients were enrolled; entry criteria were: (i) patient underwent surgery; (ii) at least 2 years of follow-up; (iii) observation time up to 2015. Data from 34 variables were collected; grading was assessed and compared for efficacy by statistical means including Kaplan-Meier method, Cox regression analysis, Harrell’s C statistics, and Royston’s explained variation in univariable and multivariable analyses. Results: In descriptive analysis, the two grading systems demonstrated statistically significant differences for the major category sex but not for age groups. In Cox regression analysis, both grading systems showed statistically significant differences between grades for OS and EFS; however, no statistically significant difference was observed between the two G3 classes of WHO-AJCC 2017. In multivariable analysis for the two models fitted to compare efficacy, the two grading systems performed equally well with substantially similar optimal discrimination and well-explained variation for both OS and EFS. The WHO-AJCC 2017 grading system retained statistically significant difference between the two G3 classes for OS but not for EFS. Conclusions: The WHO-AJCC 2017 grading system is at least equally performing as the WHO-AJCC 2010 but allows the successful identification of the most aggressive PanNET subgroup. Grading is confirmed as probably the most powerful tool for predicting patient survival.
Subject
Cellular and Molecular Neuroscience,Endocrine and Autonomic Systems,Endocrinology,Endocrinology, Diabetes and Metabolism
Reference20 articles.
1. Vélayoudom-Céphise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013 Aug;20(5):649–57. 2. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013 Jan;24(1):152–60. 3. Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, et al. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol. 2015 May;50(5):564–72. 4. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015 May;39(5):683–90. 5. Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, et al.; other Knowledge Network members. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015 Aug;22(4):657–64.
Cited by
85 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|